Evaluating the impact of COVID-19 on cancer care: a comprehensive analysis of treatment modifications, risk factors, and patient outcomes.

Background: Cancer patients will have an increased incidence of corona virus disease 2019 (COVID-19) infection. The severity of COVID-19 infection varies among cancer patients who have other complications and are being treated.

Method: This retrospective cohort study evaluated the impact of cancer treatments on COVID-19 incidence and outcomes in 603 cancer patients.

Macrophages in the premetastatic and metastatic niche: key functions and therapeutic directions.

Metastasis plays a significant role in the high mortality rates associated with cancer and is usually the endpoint of a series of sequential and dynamic events. A crucial step in metastasis development and progression is the formation of a premetastatic niche (PMN), which provides a conducive microenvironment for the settlement and colonization of disseminated tumor cells at distant metastatic sites. Extensive research has demonstrated the significance of macrophage populations within primary tumors in promoting metastatic progression.

Formation of metal-microplastic complexes in lung adenocarcinoma is associated with increased risk of cancer progression.

Metal-microplastic complexes (m-MPs) represent an emerging environmental health concern. However their presence and pathological implications in lung adenocarcinoma (LUAD) remain underexplored. This study employed a multimodal approach to characterize m-MPs in 15 LUAD patients, integrating several techniques, including laser direct infrared imaging (LDIR), pyrolysis gas chromatography-mass spectrometry (Py-GCMS), inductively coupled plasma analysis (ICP), and Sequencing at the transcriptome level.

Construction of a nomogram to guide prophylactic cranial irradiation in extensive‑stage small cell lung cancer.

Patients with extensive-stage small cell lung cancer (ES-SCLC) have a high risk of brain metastasis (BM). However, to the best of our knowledge, the risk factors for BM remain unclear. The present study aimed to investigate the risk factors and establish a prediction model for BM in patients with ES-SCLC.

Real-world data on immunotherapy combined with chemotherapy in elderly patients with extensive-stage small cell lung cancer.

Background: Immunotherapy combined with chemotherapy has shown good results in the treatment of extensive-stage small cell lung cancer (ES-SCLC), but there are fewer clinical studies on elderly ES-SCLC patients. This study was aimed to evaluate the efficacy and safety of immunotherapy in combination with chemotherapy in elderly patients with ES-SCLC.

Methods: Elderly patients with ES-SCLC who were 70 years of age or older and were diagnosed at Shandong Cancer Hospital from May 20, 2020, to February 24, 2023, were included in this study.

Role of circular RNAs in cancer therapy resistance.

Over the past decade, circular RNAs (circRNAs) have gained recognition as a novel class of genetic molecules, many of which are implicated in cancer pathogenesis via different mechanisms, including drug resistance, immune escape, and radio-resistance. ExosomalcircRNAs, in particular, facilitatecommunication between tumour cells and micro-environmental cells, including immune cells, fibroblasts, and other components. Notably, micro-environmental cells can reportedly influence tumour progression and treatment resistance by releasing exosomalcircRNAs.

The incidence of and risk factors for radiation pneumonitis in patients treated with simultaneous bevacizumab and thoracic radiotherapy.

Background: First-line chemotherapy combined with bevacizumab is one of the standard treatment modes for patients with advanced non-small cell lung cancer (NSCLC). Thoracic radiotherapy (TRT) can provide significant local control and survival benefits to patients during the treatment of advanced NSCLC. However, the safety of adding TRT has always been controversial, especially because of the occurrence of radiation pneumonia (RP) during bevacizumab treatment.

Immunotherapy combined with cranial radiotherapy for driver-negative non-small-cell lung cancer brain metastases: a retrospective study.

This study assesses immune checkpoint inhibitors' efficacy for non-small-cell lung cancer (NSCLC) with brain metastases (BM) and explores the role of cranial radiation therapy (CRT) in the immunotherapy era. The retrospective analysis screened NSCLC patients with BMs from July 2018 to December 2021. Treatment involved chemotherapy combined with immune checkpoint inhibitors as the first-line, with patients divided into CRT and non-CRT groups.

Re-evaluating the risk factors for radiation pneumonitis in the era of immunotherapy.

As one of the common complications of radiotherapy, radiation pneumonia (RP) limits the prognosis of patients. Therefore, better identifying the high-risk factors that lead to RP is essential to effectively prevent its occurrence. However, as lung cancer treatment modalities are being replaced and the era of immunotherapy has arrived, literature that reviews the parameters and mode of radiotherapy, chemotherapy drugs, targeted drugs and current hot immune checkpoint inhibitors related to RP is lacking.